Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study
Hypertensive pregnancy disorder is among the leading causes of maternal and fetal mortality, affecting 5–7% of pregnant women. Beta-blockers are known to improve endothelial dysfunction and may be beneficial in the treatment of this condition. We carried out a retrospective observational study invol...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-03-01
|
| Series: | Journal of Cardiovascular Emergencies |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/jce-2025-0001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850266111776391168 |
|---|---|
| author | Buicu Corneliu-Florin Mitranovici Melinda-Ildiko Voidazan Septimiu Craina Marius |
| author_facet | Buicu Corneliu-Florin Mitranovici Melinda-Ildiko Voidazan Septimiu Craina Marius |
| author_sort | Buicu Corneliu-Florin |
| collection | DOAJ |
| description | Hypertensive pregnancy disorder is among the leading causes of maternal and fetal mortality, affecting 5–7% of pregnant women. Beta-blockers are known to improve endothelial dysfunction and may be beneficial in the treatment of this condition. We carried out a retrospective observational study involving 80 pregnant women with hypertension, admitted to the Alexandru Simionescu County Hospital, Hunedoara, Romania, from May 1, 2021 to December 31, 2023. Systolic blood pressure, diastolic blood pressure, and hypertension treatment were compared between patients receiving metoprolol and patients receiving other antihypertensive medication. Preeclampsia and premature delivery occurred in a significantly higher proportion among those who received other antihypertensive medication (p = 0.006 and p = 0.021, respectively). Low Apgar score (Apgar 6) was encountered in 2.5% of cases. Intrauterine growth restriction did not occur in either study group, and the neonatal and maternal mortality rates were zero in both groups. Metoprolol had demonstrated its benefits in treating hypertensive pregnancy disorders. The final goal is improving maternal and fetal outcomes. |
| format | Article |
| id | doaj-art-7a9e95cebfd848818db5fb7924fe1e63 |
| institution | OA Journals |
| issn | 2457-5518 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Journal of Cardiovascular Emergencies |
| spelling | doaj-art-7a9e95cebfd848818db5fb7924fe1e632025-08-20T01:54:15ZengSciendoJournal of Cardiovascular Emergencies2457-55182025-03-01111202510.2478/jce-2025-0001Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center StudyBuicu Corneliu-Florin0Mitranovici Melinda-Ildiko1Voidazan Septimiu2Craina Marius3George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, RomaniaDepartment of Obstetrics and Gynecology, Emergency County Hospital, Hunedoara, RomaniaGeorge Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, RomaniaDepartment of Obstetrics and Gynecology, Victor Babeș University of Medicine and Pharmacy, Timișoara, RomaniaHypertensive pregnancy disorder is among the leading causes of maternal and fetal mortality, affecting 5–7% of pregnant women. Beta-blockers are known to improve endothelial dysfunction and may be beneficial in the treatment of this condition. We carried out a retrospective observational study involving 80 pregnant women with hypertension, admitted to the Alexandru Simionescu County Hospital, Hunedoara, Romania, from May 1, 2021 to December 31, 2023. Systolic blood pressure, diastolic blood pressure, and hypertension treatment were compared between patients receiving metoprolol and patients receiving other antihypertensive medication. Preeclampsia and premature delivery occurred in a significantly higher proportion among those who received other antihypertensive medication (p = 0.006 and p = 0.021, respectively). Low Apgar score (Apgar 6) was encountered in 2.5% of cases. Intrauterine growth restriction did not occur in either study group, and the neonatal and maternal mortality rates were zero in both groups. Metoprolol had demonstrated its benefits in treating hypertensive pregnancy disorders. The final goal is improving maternal and fetal outcomes.https://doi.org/10.2478/jce-2025-0001hypertensive pregnancy disorderpreeclampsiametoprolol |
| spellingShingle | Buicu Corneliu-Florin Mitranovici Melinda-Ildiko Voidazan Septimiu Craina Marius Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study Journal of Cardiovascular Emergencies hypertensive pregnancy disorder preeclampsia metoprolol |
| title | Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study |
| title_full | Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study |
| title_fullStr | Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study |
| title_full_unstemmed | Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study |
| title_short | Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study |
| title_sort | metoprolol use in hypertensive pregnancy disorder a single center study |
| topic | hypertensive pregnancy disorder preeclampsia metoprolol |
| url | https://doi.org/10.2478/jce-2025-0001 |
| work_keys_str_mv | AT buicucorneliuflorin metoprololuseinhypertensivepregnancydisorderasinglecenterstudy AT mitranovicimelindaildiko metoprololuseinhypertensivepregnancydisorderasinglecenterstudy AT voidazanseptimiu metoprololuseinhypertensivepregnancydisorderasinglecenterstudy AT crainamarius metoprololuseinhypertensivepregnancydisorderasinglecenterstudy |